AbbVie (ABBV) Non-Current Deferred Tax Liability (2012 - 2026)

AbbVie (ABBV) has 15 years of Non-Current Deferred Tax Liability data on file, last reported at $2.3 billion in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $2.3 billion, down 9.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 billion (down 9.68% YoY), and the FY2025 annual result was $2.4 billion, down 20.07% from the prior year.
• Non-Current Deferred Tax Liability fell to $2.3 billion in Q1 2026 per ABBV's latest filing, from $2.4 billion in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $4.7 billion in Q4 2022 and troughed at $2.0 billion in Q3 2022.
• A 5-year average of $2.6 billion and a median of $2.6 billion in 2025 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2024: Non-Current Deferred Tax Liability tumbled 45.25% in 2022, then jumped 34.49% in 2024.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $4.7 billion in 2022, then plunged by 43.53% to $2.7 billion in 2023, then rose by 12.58% to $3.0 billion in 2024, then declined by 20.07% to $2.4 billion in 2025, then retreated by 2.39% to $2.3 billion in 2026.
• Business Quant data shows ABBV's Non-Current Deferred Tax Liability at $2.3 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.5 billion in Q3 2025.